Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014 (2014), Article ID 724258, 11 pages
http://dx.doi.org/10.1155/2014/724258
Research Article

Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients

1Research Institute Havelhoehe, 14089 Berlin, Germany
2Hospital Havelhoehe, 14089 Berlin, Germany
3Institute for Social Medicine, Epidemiology and Health Economics, Charité-University Medical Center, 10117 Berlin, Germany

Received 23 September 2013; Accepted 16 December 2013; Published 19 January 2014

Academic Editor: Gene Feder

Copyright © 2014 Megan L. Steele et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Horneber, G. Bueschel, G. Dennert, D. Less, and M. Zwahlen, “How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis,” Integrative Cancer Therapies, vol. 11, no. 3, pp. 187–203, 2012. View at Publisher · View at Google Scholar
  2. G. S. Kienle, H. Kiene, and H. U. Albonico, “Anthroposophic medicine: health technology assessment report—short version,” Forschende Komplementarmedizin, vol. 13, supplement 2, pp. 7–18, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. M. A. Horneber, G. Bueschel, R. Huber, K. Linde, and M. Rostock, “Mistletoe therapy in oncology,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD003297, 2008. View at Google Scholar · View at Scopus
  4. J. W. Zeller, “Immuntherapeutika und zytostatika,” in Arzneimittelverordnungs-Report 2004, U. Schwabe and D. Paffrath, Eds., pp. 609–624, Springer, Berlin, Germany, 2004. View at Google Scholar
  5. G. Seifert, P. Jesse, A. Laengler et al., “Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro,” Cancer Letters, vol. 264, no. 2, pp. 218–228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. N. E. Gardin, “Immunological response to mistletoe (Viscum album L.) in cancer patients: a four-case series,” Phytotherapy Research, vol. 23, no. 3, pp. 407–411, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Hostanska, T. Hajto, G. C. Spagnoli, J. Fischer, H. Lentzen, and R. Herrman, “A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells,” Natural Immunity, vol. 14, no. 5-6, pp. 295–304, 1995. View at Google Scholar · View at Scopus
  8. R. Huber, K. Claßen, M. Werner, and R. Klein, “In vitro immunoreactivity towards lectin-rich or viscotoxin-rich mistletoe (Viscum album L.) extracts iscador applied to healthy individuals: a randomised double-blind placebo controlled study,” Arzneimittel-Forschung, vol. 56, no. 6, pp. 447–456, 2006. View at Google Scholar · View at Scopus
  9. C. Jaggy, H. Musielski, K. Urech, and G. Schaller, “Quantitative determination of lectins in mistletoe preparations,” Arzneimittel-Forschung, vol. 45, no. 8, pp. 905–909, 1995. View at Google Scholar · View at Scopus
  10. T. Ostermann, C. Raak, and A. Büssing, “Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review,” BMC Cancer, vol. 9, article 451, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. G. S. Kienle, A. Glockmann, M. Schink, and H. Kiene, “Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research,” Journal of Experimental and Clinical Cancer Research, vol. 28, no. 1, article no. 79, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Beuth, B. Schneider, and J. M. Schierholz, “Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative Epidemiological Cohort Study,” Anticancer Research, vol. 28, no. 1, pp. 523–527, 2008. View at Google Scholar · View at Scopus
  13. J. Melzer, F. Iten, K. Hostanska, and R. Saller, “Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases,” Forschende Komplementarmedizin, vol. 16, no. 4, pp. 217–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Büssing, C. Raak, and T. Ostermann, “Quality of life and related dimensions in cancer patients treated with mistletoe extract (Iscador): a meta-analysis,” Evidence-based Complementary and Alternative Medicine, vol. 2012, Article ID 219402, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Matthes, W. E. Friedel, P. R. Bock, and K. S. Zänker, “Molecular mistletoe therapy: friend or foe in established antitumor protocols? a multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer,” Current Molecular Medicine, vol. 10, no. 4, pp. 430–439, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Eisenbraun, R. Scheer, M. Kröz, F. Schad, and R. Huber, “Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract,” Phytomedicine, vol. 18, no. 2-3, pp. 151–157, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Heusser, S. B. Braun, M. Bertschy et al., “Palliative in-patient cancer treatment in an anthroposophic hospital: II. Quality of life during and after stationary treatment, and subjective treatment benefits,” Forschende Komplementarmedizin, vol. 13, no. 3, pp. 156–166, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. S. P. Myers and P. A. Cheras, “The other side of the coin: safety of complementary and alternative medicine,” Medical Journal of Australia, vol. 181, no. 4, pp. 222–225, 2004. View at Google Scholar · View at Scopus
  19. M. Tascilar, F. A. de Jong, J. Verweij, and R. H. J. Mathijssen, “Complementary and alternative medicine during cancer treatment: beyond innocence,” Oncologist, vol. 11, no. 7, pp. 732–741, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. B. R. Cassileth and G. Deng, “Complementary and alternative therapies for cancer,” Oncologist, vol. 9, no. 1, pp. 80–89, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. K. C. Kim, J. H. Yook, J. Eisenbraun, B. S. Kim, and R. Huber, “Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma—a randomized, controlled pilot study,” BMC Complementary and Alternative Medicine, vol. 12, article 172, 2012. View at Publisher · View at Google Scholar
  22. R. Huber, H. Lüdtke, J. Wieber, and C. Beckmann, “Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters—a placebo controlled clinical trial in healthy subjects,” BMC Complementary and Alternative Medicine, vol. 11, article 116, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Schad, C. Teodoridis, U. Albrecht et al., “Network oncology (NO)—a European approach to health service research on cancer treatment with focus on concurrent use of complementary therapies,” European Journal of Integrative Medicine, vol. 1, supplement 1, pp. 12–13, 2008. View at Google Scholar
  24. F. Schad, J. Axtner, A. Happe et al., “Network oncology (NO)—a clinical cancer register for health services research and the evaluation of integrative therapeutic interventions in anthroposophic medicine,” Research in Complementary Medicine, vol. 20, pp. 353–360, 2013. View at Publisher · View at Google Scholar
  25. F. Schad, J. Pissarek, U. Albrecht, and H. Matthes, “QuaDoSta (quality assurance, documentation and statistics)—a flexible, platform-independent, open source database for oncological documentation,” Cancer Research and Clinical Oncology, vol. 130, supplement op, p. 785, 2004. View at Google Scholar
  26. E. Jeschke, F. Schad, J. Pissarek, B. Matthes, U. Albrecht, and H. Matthes, “QuaDoSta—a freely configurable system which facilitates multi-centric data collection for healthcare and medical research,” GMS Medizinische Informatik, Biometrie und Epidemiologie, vol. 3, no. 2, 2007. View at Google Scholar
  27. R Core Team, “R: A language and environment for statistical computing,” in R Foundation for Statistical Computing, 2012.
  28. UMC, “Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre,” http://www.who.int/medicinedocs.
  29. ICH, “E2A: clinical safety data management: definitions and standards for expedited reporting,” http://www.ich.org.
  30. CTEP, “Common terminology criteria for adverse events,” http://ctep.cancer.gov/protocolDevelopment.
  31. “Arzneimittelinformation AbnobaVISCUM,” 2007, http://www.abnoba.de.
  32. “Iscador: Anthroposophisches Arzneimittel. Fachinformation des Arzneimittel-Kompendium der Schweiz,” 2007, http://www.weleda.de.
  33. “Helixor: Anthroposophische Arzneimittel. Fachinformation des Arzneimittel-Kompendium der Schweiz,” 2007, http://www.helixor.de.
  34. J. Concato, P. Peduzzi, T. R. Holford, and A. R. Feinstein, “Importance of events per independent variable in proportional hazards analysis I. Background, goals, and general strategy,” Journal of Clinical Epidemiology, vol. 48, no. 12, pp. 1495–1501, 1995. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Peduzzi, J. Concato, A. R. Feinstein, and T. R. Holford, “Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates,” Journal of Clinical Epidemiology, vol. 48, no. 12, pp. 1503–1510, 1995. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Peduzzi, J. Concato, E. Kemper, T. R. Holford, and A. R. Feinstem, “A simulation study of the number of events per variable in logistic regression analysis,” Journal of Clinical Epidemiology, vol. 49, no. 12, pp. 1373–1379, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. P. R. Bock, W. E. Friedel, J. Hanisch, M. Karasmann, and B. Schneider, “Efficacy and safety of long-term complementary treatment with standardized european mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma / results of a multicenter, comparative, epidemiological Cohort study in Germany and Switzerland,” Arzneimittel-Forschung, vol. 54, no. 8, pp. 456–466, 2004. View at Google Scholar · View at Scopus
  38. G. S. Kienle, R. Grugel, and H. Kiene, “Safety of higher dosages of Viscum album L. in animals and humans—systematic review of immune changes and safety parameters,” BMC Complementary and Alternative Medicine, vol. 11, article 72, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. CIOMS, Guidelines for Preparing Core Clinical-Safety InFormation on Drugs, Council for International Organizations of Medical Sciences, Geneva, Switzerland, 2nd edition, 1999.
  40. M. Radenkovic, V. Ivetic, M. Popovic, S. Brankovic, and L. Gvozdenovic, “Effects of mistletoe (Viscum album L., Loranthaceae) extracts on arterial blood pressure in rats treated with atropine sulfate and hexocycline,” Clinical and Experimental Hypertension, vol. 31, no. 1, pp. 11–19, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Penter, “Methodische aspekte zu einer goetheanistisch-anthroposophischen klinischen forschung am beispiel der entwicklung der mistelfiebertherapie,” Der Merkurstab, vol. 5, pp. 350–368, 2002. View at Google Scholar
  42. O. Adaramoye, M. Amanlou, M. Habibi-Rezaei, P. Pasalar, and M. Ali, “Methanolic extract of African mistletoe (Viscum album) improves carbohydrate metabolism and hyperlipidemia in streptozotocin-induced diabetic rats,” Asian Pacific Journal of Tropical Medicine, vol. 5, no. 6, pp. 427–433, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Frederick, A. Kayode, and U. Slyvester, “Evaluation of the methanolic extract of mistletoe (Tapinanthus bangwensis) leaves grown on orange trees for the phytochemical properties and its physiological effects on streptozotocin induced diabetes mellitus in laboratory animals,” World Applied Sciences Journal, vol. 9, no. 9, pp. 975–979, 2010. View at Google Scholar
  44. M. Tabali, E. Jeschke, A. Bockelbrink et al., “Educational intervention to improve physician reporting of adverse drug reactions (ADRs) in a primary care setting in complementary and alternative medicine,” BMC Public Health, vol. 9, article 274, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Tabali, T. Ostermann, E. Jeschke, C. M. Witt, and H. Matthes, “Adverse drug reactions for CAM and conventional drugs detected in a network of physicians certified to prescribe CAM drugs,” Journal of Managed Care Pharmacy, vol. 18, no. 6, pp. 427–438, 2012. View at Google Scholar
  46. M. Süsskind, P. A. Thürmann, C. Lüke et al., “Adverse drug reactions in a complementary medicine hospital: a prospective, intensified surveillance study,” Evidence-based Complementary and Alternative Medicine, vol. 2012, Article ID 320760, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Fischer, A. Scheffler, and D. Kabelitz, “Stimulation of the specific immune system by mistletoe extracts,” Anti-Cancer Drugs, vol. 8, supplement 1, pp. S33–S37, 1997. View at Google Scholar · View at Scopus
  48. G. Stein, W. Henn, H. von Laue, and P. Berg, “Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy,” European Journal of Medical Research, vol. 3, no. 4, pp. 194–202, 1998. View at Google Scholar · View at Scopus
  49. H. B. von Laue and W. Henn, “Zeitphänomene der krebskrankheit,” Deutsche Zeitschrift für Onkologie, vol. 23, pp. 64–73, 1991. View at Google Scholar
  50. K. M. Kokolus, C. Hong, and E. A. Repasky, “Feeling too hot or cold after breast cancer: is it just a nuisance or a potentially important prognostic factor?” International Journal of Hyperthermia, vol. 26, no. 7, pp. 662–680, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. E. M. Bessell, C. Selby, and I. O. Ellis, “Severe hypoglycaemia caused by raised insulin-like growth factor II in disseminated breast cancer,” Journal of Clinical Pathology, vol. 52, no. 10, pp. 780–781, 1999. View at Google Scholar · View at Scopus
  52. R. Valdagni and M. Amichetti, “Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymphnodes in stage IV head and neck patients,” International Journal of Radiation Oncology Biology Physics, vol. 28, no. 1, pp. 163–169, 1994. View at Google Scholar · View at Scopus
  53. E. L. Jones, J. R. Oleson, L. R. Prosnitz et al., “Randomized trial of hyperthermia and radiation for superficial tumors,” Journal of Clinical Oncology, vol. 23, no. 13, pp. 3079–3085, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. J. van der Zee, D. González González, G. C. van Rhoon, J. D. P. van Dijk, W. L. J. van Putten, and A. A. M. Hart, “Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial,” The Lancet, vol. 355, no. 9210, pp. 1119–1125, 2000. View at Google Scholar · View at Scopus
  55. K. Sugimachi, H. Kuwano, H. Ide, T. Toge, M. Saku, and Y. Oshiumi, “Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospective randomized trial,” International Journal of Hyperthermia, vol. 10, no. 4, pp. 485–493, 1994. View at Google Scholar · View at Scopus
  56. K. Sugimachi, K. Kitamura, K. Baba et al., “Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the oesophagus—a prospective randomized trial,” International Journal of Hyperthermia, vol. 8, no. 3, pp. 289–295, 1992. View at Google Scholar · View at Scopus
  57. A. J. Peer, M. J. Grimm, E. R. Zynda, and E. A. Repasky, “Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia,” Immunologic Research, vol. 46, no. 1–3, pp. 137–154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Saller, S. Kramer, F. Iten, and J. Melzer, “Unerwünschte wirkungen der misteltherapie bei tumorpatienten—eine systematische Übersicht,” in Fortschritte in der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung, R. Scheer, H. Bauer, V. Becker et al., Eds., pp. 367–403, KVC, Essen, Germany, 2005. View at Google Scholar
  59. R. M. Martin, P. N. Biswas, S. N. Freemantle, G. L. Pearce, and R. D. Mann, “Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: Analysis of 48 Cohort studies,” British Journal of Clinical Pharmacology, vol. 46, no. 5, pp. 505–511, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Zopf, C. Rabe, A. Neubert et al., “Women encounter ADRs more often than do men,” European Journal of Clinical Pharmacology, vol. 64, no. 10, pp. 999–1004, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. S. Ali, N. Daamen, J. Giris et al., “Orthostatic intolerance: a disorder of young women,” Obstetrical and Gynecological Survey, vol. 55, no. 4, pp. 251–259, 2000. View at Publisher · View at Google Scholar
  62. L. Rasmussen and A. Arvin, “Chemotherapy-induced immunosuppression,” Environmental Health Perspectives, vol. 43, pp. 21–25, 1982. View at Google Scholar · View at Scopus
  63. N. Rouas-Freiss, P. Moreau, C. Menier, and E. D. Carosella, “HLA-G in cancer: a way to turn off the immune system,” Seminars in Cancer Biology, vol. 13, no. 5, pp. 325–336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. P. J. Mansky, J. Grem, D. B. Wallerstedt, B. P. Monahan, and M. R. Blackman, “Mistletoe and gemcitabine in patients with advanced cancer: a model for the phase I study of botanicals and botanical-drug interactions in cancer therapy,” Integrative Cancer Therapies, vol. 2, no. 4, pp. 345–352, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. P. J. Mansky, D. B. Wallerstedt, T. Sannes et al., “NCCAM/NCI phase I study of mistletoe extract and gemcitabine in patients with advanced solid tumors,” Journal of Clinical Oncology, vol. 28, supplement 2559, no. 15, 2010. View at Google Scholar
  66. B. K. Piao, Y. X. Wang, G. R. Xie et al., “Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial,” Anticancer Research, vol. 24, no. 1, pp. 303–309, 2004. View at Google Scholar · View at Scopus
  67. M. M. Reidenberg and D. T. Lowenthal, “Adverse nondrug reactions,” The New England Journal of Medicine, vol. 279, no. 13, pp. 678–679, 1968. View at Google Scholar · View at Scopus